Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium.

Geijsen AJMR, van Roekel EH, van Duijnhoven FJB, Achaintre D, Bachleitner-Hofmann T, Baierl A, Bergmann MM, Boehm J, Bours MJL, Brenner H, Breukink SO, Brezina S, Chang-Claude J, Herpel E, de Wilt JHW, Gicquiau A, Gigic B, Gumpenberger T, Hansson BME, Hoffmeister M, Holowatyj AN, Karner-Hanusch J, Keski-Rahkonen P, Keulen ETP, Koole JL, Leeb G, Ose J, Schirmacher P, Schneider MA, Schrotz-King P, Stift A, Ulvik A, Vogelaar FJ, Wesselink E, van Zutphen M, Gsur A, Habermann N, Kampman E, Scalbert A, Ueland PM, Ulrich AB, Ulrich CM, Weijenberg MP, Kok DE.

Int J Cancer. 2019 Sep 8. doi: 10.1002/ijc.32666. [Epub ahead of print]

PMID:
31495913
2.

Outcome of no oral antibiotic prophylaxis and bowel preparation in Crohn's diseases surgery.

Unger LW, Riss S, Argeny S, Bergmann M, Bachleitner-Hofmann T, Herbst F, Stift A.

Wien Klin Wochenschr. 2019 Mar;131(5-6):113-119. doi: 10.1007/s00508-019-1475-8. Epub 2019 Mar 6.

3.

Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile.

Strasser K, Birnleitner H, Beer A, Pils D, Gerner MC, Schmetterer KG, Bachleitner-Hofmann T, Stift A, Bergmann M, Oehler R.

Oncoimmunology. 2018 Nov 5;8(2):e1537693. doi: 10.1080/2162402X.2018.1537693. eCollection 2019.

4.

Plasma metabolites associated with colorectal cancer: A discovery-replication strategy.

Geijsen AJMR, Brezina S, Keski-Rahkonen P, Baierl A, Bachleitner-Hofmann T, Bergmann MM, Boehm J, Brenner H, Chang-Claude J, van Duijnhoven FJB, Gigic B, Gumpenberger T, Hofer P, Hoffmeister M, Holowatyj AN, Karner-Hanusch J, Kok DE, Leeb G, Ulvik A, Robinot N, Ose J, Stift A, Schrotz-King P, Ulrich AB, Ueland PM, Kampman E, Scalbert A, Habermann N, Gsur A, Ulrich CM.

Int J Cancer. 2019 Sep 1;145(5):1221-1231. doi: 10.1002/ijc.32146. Epub 2019 Feb 14.

5.

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.

Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A.

BMC Cancer. 2018 Dec 4;18(1):1210. doi: 10.1186/s12885-018-5126-7.

6.

Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.

Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S.

Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. doi: 10.1097/IGC.0000000000001369.

PMID:
30371563
7.

Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.

Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Schönthaler S, Taghizadeh H, Stremitzer S, Kaczirek K, Gruenberger T, Gnant M, Bergmann M, Mannhalter C, Weinhäusel A, Oehler R, Bachleitner-Hofmann T.

Ann Surg. 2018 Nov;268(5):894-902. doi: 10.1097/SLA.0000000000002901.

PMID:
30080722
8.

Leukocyte telomere length throughout the continuum of colorectal carcinogenesis.

Zöchmeister C, Brezina S, Hofer P, Baierl A, Bergmann MM, Bachleitner-Hofmann T, Karner-Hanusch J, Stift A, Gerger A, Leeb G, Mach K, Rachakonda S, Kumar R, Gsur A.

Oncotarget. 2018 Feb 7;9(17):13582-13592. doi: 10.18632/oncotarget.24431. eCollection 2018 Mar 2.

9.

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.

Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. No abstract available.

10.

Bayesian and frequentist analysis of an Austrian genome-wide association study of colorectal cancer and advanced adenomas.

Hofer P, Hagmann M, Brezina S, Dolejsi E, Mach K, Leeb G, Baierl A, Buch S, Sutterlüty-Fall H, Karner-Hanusch J, Bergmann MM, Bachleitner-Hofmann T, Stift A, Gerger A, Rötzer K, Karner J, Stättner S, Waldenberger M, Meitinger T, Strauch K, Linseisen J, Gieger C, Frommlet F, Gsur A.

Oncotarget. 2017 Oct 9;8(58):98623-98634. doi: 10.18632/oncotarget.21697. eCollection 2017 Nov 17.

11.

Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.

Bhangu JS, Taghizadeh H, Braunschmid T, Bachleitner-Hofmann T, Mannhalter C.

Surg Oncol. 2017 Dec;26(4):395-401. doi: 10.1016/j.suronc.2017.08.001. Epub 2017 Aug 7.

PMID:
29113658
12.

Trocar-site evisceration of the vermiform appendix following laparoscopic sigmoid colectomy: A case report.

Bhangu JS, Exner R, Bachleitner-Hofmann T.

Int J Surg Case Rep. 2017;31:273-275. doi: 10.1016/j.ijscr.2017.01.066. Epub 2017 Feb 1.

13.

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Cancer Med. 2016 Sep;5(9):2350-8. doi: 10.1002/cam4.827. Epub 2016 Jul 25.

14.

The type of loose seton for complex anal fistula is essential to improve perianal comfort and quality of life.

Kristo I, Stift A, Staud C, Kainz A, Bachleitner-Hofmann T, Chitsabesan P, Riss S.

Colorectal Dis. 2016 Jun;18(6):O194-8. doi: 10.1111/codi.13335.

PMID:
26999764
15.

Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues.

Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D.

Sci Rep. 2015 Jan 27;5:8057. doi: 10.1038/srep08057.

16.

Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.

Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R.

Oncologist. 2015 Feb;20(2):127-33. doi: 10.1634/theoncologist.2014-0325. Epub 2015 Jan 5.

17.

The Comfort Drain: a new device for treating complex anal fistula.

Riss S, Bachleitner-Hofmann T, Stift A.

Tech Coloproctol. 2014 Nov;18(11):1133-5. doi: 10.1007/s10151-014-1216-y. Epub 2014 Sep 26. No abstract available.

PMID:
25258242
18.

American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Esquivel J, Piso P, Verwaal V, Bachleitner-Hofmann T, Glehen O, González-Moreno S, Deraco M, Pelz J, Alexander R, Glockzin G.

J Surg Oncol. 2014 Dec;110(7):777-8. doi: 10.1002/jso.23722. Epub 2014 Jul 8. No abstract available.

PMID:
25043759
19.

Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, Moran B.

Eur J Surg Oncol. 2013 Sep;39(9):931-7. doi: 10.1016/j.ejso.2013.06.001. Epub 2013 Jun 27. Review.

PMID:
23810280
20.

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.

Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Eur J Clin Invest. 2013 Mar;43(3):286-91. doi: 10.1111/eci.12043. Epub 2013 Jan 25.

PMID:
23410002
21.

Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer.

Schauer D, Starlinger P, Reiter C, Jahn N, Zajc P, Buchberger E, Bachleitner-Hofmann T, Bergmann M, Stift A, Gruenberger T, Brostjan C.

PLoS One. 2012;7(9):e44450. doi: 10.1371/journal.pone.0044450. Epub 2012 Sep 4.

22.

Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Clin Cancer Res. 2011 Jan 1;17(1):122-33. doi: 10.1158/1078-0432.CCR-10-0253.

23.

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR.

Clin Cancer Res. 2011 Feb 1;17(3):472-82. doi: 10.1158/1078-0432.CCR-10-0568. Epub 2010 Nov 22.

24.

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R.

Br J Cancer. 2010 Oct 12;103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28.

25.

Mesh graft infection following abdominal hernia repair: risk factor evaluation and strategies of mesh graft preservation. A retrospective analysis of 476 operations.

Stremitzer S, Bachleitner-Hofmann T, Gradl B, Gruenbeck M, Bachleitner-Hofmann B, Mittlboeck M, Bergmann M.

World J Surg. 2010 Jul;34(7):1702-9. doi: 10.1007/s00268-010-0543-z.

PMID:
20372901
26.

Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells.

Wirtitsch M, Roth E, Bachleitner-Hofmann T, Wessner B, Sturlan S.

Oncol Res. 2009;18(2-3):83-94.

PMID:
20066898
27.

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G.

Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20. Review.

PMID:
19686352
28.

Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy.

Hayden H, Friedl J, Dettke M, Sachet M, Hassler M, Dubsky P, Bachleitner-Hofmann T, Gnant M, Stift A.

J Immunother. 2009 Jul-Aug;32(6):638-54. doi: 10.1097/CJI.0b013e3181a5bc13.

PMID:
19483645
29.

Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.

Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R, Brostjan C, Riss S, Niederle B, Gnant M, Stift A.

Oncol Rep. 2009 Jun;21(6):1585-92.

PMID:
19424640
30.

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio.

Blaha P, Exner R, Borgo AD, Bigenzahn S, Panhofer P, Riedl O, Schoppmann S, Bachleitner-Hofmann T, Sporn E, Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M.

Breast Care (Basel). 2009;4(3):155-161. Epub 2009 Jun 23.

31.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

32.

Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture.

Dubsky P, Hayden H, Sachet M, Bachleitner-Hofmann T, Hassler M, Pfragner R, Gnant M, Stift A, Friedl J.

Cancer Immunol Immunother. 2008 Jun;57(6):859-70. Epub 2007 Nov 21.

PMID:
18030468
33.

Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients.

Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, Handl-Zeller L, Dubsky P, Bachleitner-Hofmann T, Steger G, Jakesz R, Gnant M.

Breast Cancer Res Treat. 2007 May;103(1):45-52. Epub 2007 Apr 7.

PMID:
17417725
34.

Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma.

Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann SF, Pfragner R, Gnant M, Friedl J, Stift A.

J Clin Endocrinol Metab. 2006 Nov;91(11):4571-7. Epub 2006 Sep 5.

PMID:
16954161
35.

Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.

Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P.

Breast Cancer Res Treat. 2006 Sep;99(2):135-41. Epub 2006 Mar 23.

PMID:
16555123
36.

Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells.

Dubsky PC, Friedl J, Stift A, Bachleitner-Hofmann T, Jakesz R, Gnant MF, Weigel G.

Clin Chim Acta. 2006 Feb;364(1-2):139-47. Epub 2005 Jul 26.

PMID:
16051207
37.

Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study.

Gisslinger H, Müllner M, Pabinger I, Heis-Vahidi-Fard N, Gisslinger B, Brichta A, Bachleitner-Hofmann T, Mannhalter C.

Haematologica. 2005 Mar;90(3):408-10.

38.

Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells.

Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner-Hofmann T.

Int J Cancer. 2004 Nov 20;112(4):707-12.

39.

High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.

Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R.

Eur J Surg Oncol. 2004 Apr;30(3):243-7.

PMID:
15028303
40.
41.

Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells.

Schueller G, Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Jakesz R, Gnant M.

Int J Oncol. 2003 Jun;22(6):1397-402.

PMID:
12739010
42.

Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.

Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T.

Blood. 2003 Jun 15;101(12):4990-7. Epub 2003 Feb 27.

PMID:
12609832
43.

In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.

Int J Oncol. 2003 Mar;22(3):651-6.

PMID:
12579320
44.

Dendritic cell-based vaccination in solid cancer.

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M.

J Clin Oncol. 2003 Jan 1;21(1):135-42.

PMID:
12506182
45.

Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.

Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Sporn E, Jakesz R.

Clin Cancer Res. 2002 Nov;8(11):3427-32.

46.

Arsenic trioxide: acute promyelocytic leukemia and beyond.

Bachleitner-Hofmann T, Kees M, Gisslinger H.

Leuk Lymphoma. 2002 Aug;43(8):1535-40. Review.

PMID:
12400595
47.

Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.

Bachleitner-Hofmann T, Machold K, Knobler R, Drach J, Grumbeck E, Gisslinger H.

Clin Exp Rheumatol. 2002 Jan-Feb;20(1):85-8.

PMID:
11892717
48.

Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells.

Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schüller G, Benkö T, Niederle B, Brostjan C, Jakesz R, Gnant M.

J Clin Endocrinol Metab. 2002 Mar;87(3):1098-104.

PMID:
11889172
49.

Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis.

Schueller G, Paolini P, Friedl J, Stift A, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M.

Anticancer Res. 2001 Jan-Feb;21(1A):295-300.

PMID:
11299751
50.

Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?

Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H.

Br J Haematol. 2001 Mar;112(3):783-6.

PMID:
11260084

Supplemental Content

Loading ...
Support Center